Chonluten
A Khavinson-class short peptide bioregulator proposed to support bronchial and lung epithelial tissue through tissue-selective gene expression regulation.
Chonluten is a respiratory bioregulator from Vladimir Khavinson's St. Petersburg Institute of Bioregulation and Gerontology, historically marketed in two overlapping forms: a polypeptide extract prepared from bovine or porcine bronchial mucosa, and a defined-sequence synthetic short peptide most commonly cited as the tripeptide Glu-Asp-Gly (EDG, ~319 Da). It is positioned to support respiratory epithelium, alveolar function, and airway regeneration in age-related pulmonary decline, COPD, and chronic bronchitis. Evidence is preclinical and limited to Khavinson-series in vitro work, rodent models, and small uncontrolled observational case series; it has no FDA, EMA, or Western regulatory approval and appears in no respiratory treatment guideline.
Class
Synthetic tripeptide (Glu-Asp-Gly) / bronchial polypeptide extract — Khavinson-class bioregulator
Half-life
Not characterized
Routes
Oral, Sublingual, Subcutaneous (synthetic EDG only)
Category
Longevity & Bioregulators
Researched benefits
What it's studied for
Respiratory mucosal support
Proposed to support bronchial epithelial repair and mucosal barrier integrity by upregulating respiratory-epithelial survival and regeneration programs. Evidence is preclinical (Khavinson in vitro bronchial cell culture) and mechanistically framework-level rather than validated.
Lung tissue regeneration and maintenance
Positioned to support alveolar cell function and pulmonary parenchymal maintenance in aging or injured lung tissue. Basis is the Khavinson organ-specific bioregulator model and rodent lung-injury experiments, not controlled human trials.
Respiratory anti-inflammatory activity
Proposed to favor anti-inflammatory transcriptional programs in respiratory epithelium. This is a hypothesized effect within the Khavinson framework; no defined inflammatory-signaling target (IL-5, IL-13, TSLP) has been identified.
Enhanced respiratory immunity
Some Russian observational users report fewer winter respiratory infections after seasonal cycles. This signal is uncontrolled and could reflect real effect, placebo, or covariates such as concurrent smoking-status or environmental changes.
Support for age-related pulmonary decline
Investigated for oxidative stress in lung tissue and age-related decline of pulmonary function as part of the anti-aging bioregulator rationale. Human data are small, uncontrolled observational series in elderly COPD and chronic bronchitis patients.
Mechanism
How it works
Chonluten falls within the Khavinson short-peptide bioregulator framework, and its proposed mechanism differs depending on which form is discussed. The historical polypeptide extract is an undefined mixture of low-molecular-weight peptides (roughly 1,000–10,000 daltons) prepared by aqueous extraction of bovine or porcine bronchial mucosa. Its proposed mechanism is tissue-derived bioregulator signalling — the idea that animal-tissue-derived peptide mixtures retain tissue-specific regulatory information that guides homologous tissue regeneration. Because the extract's composition is not defined, this claim is mechanistically vague by modern pharmacology standards and difficult to test.
The later synthetic form is the tripeptide Glu-Asp-Gly (EDG), roughly 319 daltons. The Khavinson framework proposes three layers: (1) passive membrane permeation, since EDG is small and polar enough to cross phospholipid bilayers, with tritiated-peptide biodistribution in rodents reporting lung uptake after oral or intraperitoneal dosing; (2) nuclear import by passive diffusion through nuclear pores, plausible at 319 daltons; and (3) chromatin modulation, where the peptide is proposed to make sequence-selective contacts with exposed DNA regions and histone tails, preferentially upregulating respiratory-epithelial programs such as ciliogenesis, mucin transcription, and surfactant production. This third layer is a framework-level claim and has not been validated with modern chromatin biology methods (ChIP-seq, ATAC-seq, CUT&RUN) for any Khavinson peptide.
Class-level published work provides the broader mechanistic context. Reviews of ultrashort peptides describe intracellular transport via proton-coupled oligopeptide transporter (POT) and large amino acid transporter (LAT) carrier families, proposed to underlie tissue selectivity, and systematic reviews report that short peptides of 2–7 amino acids can penetrate cell nuclei, interact with histones and DNA, and modulate gene transcription across multiple species. These class-level findings frame — but do not specifically demonstrate — chonluten's bronchial activity.
A more conservative interpretation treats EDG simply as a rapidly absorbed tripeptide delivering glutamate, aspartate, and glycine, where any effects could reflect non-specific amino-acid signalling or nutritional support to stressed respiratory tissue. Notably, no GPCR, nuclear receptor, or defined enzyme target has been identified for chonluten in either form; it does not engage the β-adrenoceptor, muscarinic, glucocorticoid, or cytokine targets exploited by evidence-graded respiratory drugs. The absence of a defined pharmacological target is characteristic of the Khavinson bioregulator class.
Dosing protocols
Dosing & administration
Dosing reflects protocols reported in research and community literature for educational purposes. It is not medical advice or a recommendation. Most peptides here are not approved for human use.
Reconstitution
Reconstitution applies only to synthetic lyophilised EDG tripeptide from research-peptide suppliers — not to oral capsules or polypeptide extract. Typical: a 5 mg vial reconstituted with 2 mL bacteriostatic water yields 2.5 mg/mL. At 2.5 mg/mL, 2 mg = 0.8 mL (80 units U100), 2.5 mg = 1.0 mL (100 units), 5 mg = 2.0 mL. Store reconstituted solution at 2–8 °C (not frozen); ~28–30 day stability. Discard if cloudy or with particulate. Do NOT reconstitute or inject the polypeptide extract form.
Beginner (first respiratory cycle)
- Dose
- 1 capsule (20 mg nominal)
- Frequency
- Once daily
- Timing
- Sublingual (hold ~60 seconds) or oral on empty stomach 30–45 min before breakfast
- Duration
- 10 consecutive days, then 60-day washout
- Route
- Oral / sublingual
Choose synthetic EDG capsule if any animal-protein allergy concern. Autumn entry before winter respiratory season is Russian convention. Continue prescribed inhalers; do not substitute. Track peak flow, dyspnoea, cough. Expect modest subjective effect at best.
Intermediate (experienced bioregulator user)
- Dose
- 20 mg oral daily OR 2–5 mg SC daily (synthetic EDG)
- Frequency
- Once daily
- Timing
- Sublingual/oral on empty stomach, or SC with site rotation
- Duration
- 10 consecutive days per cycle, cycled twice yearly (autumn and spring)
- Route
- Oral / sublingual or subcutaneous (synthetic only)
May alternate or pair sequentially with Bronchogen (AEDP). Keep a cycle log with dose, source, lot, and symptom scores. Coordinate cycles with any planned clinic spirometry. Annual Chonluten cycling roughly 150–300 USD.
Advanced (Khavinson respiratory rotation)
- Dose
- 20 mg oral (synthetic EDG preferred) OR 5 mg SC daily
- Frequency
- Once daily during active 10-day windows
- Timing
- Rotation across the year (e.g. Chonluten month 1, Bronchogen month 4, Thymogen month 7, Chonluten repeat month 10) with 2-month washouts between
- Duration
- 10-day active windows separated by washouts across a 12-month rotation
- Route
- Oral / sublingual or subcutaneous
Layer only on an evidence-graded base (inhalers continued, smoking cessation achieved, vaccinations current, pulmonary rehab done). Baseline and annual spirometry (FEV1, FVC, FEV1/FVC, peak flow) plus CBC/CMP. Notify pulmonologist of bioregulator cycles.
- A 20 mg capsule contains undisclosed actual peptide content — historically about 2–4 mg of peptide or peptide fraction for extract or synthetic forms.
- 10-days-on / 60-days-off is the uniform Khavinson convention and is not empirically optimised for chonluten specifically. Do not run continuous cycles.
- No established maximum dose; do not exceed 20 mg oral or 5 mg SC daily without clinical reason.
- Do not inject the polypeptide extract form subcutaneously without explicit vendor instructions — extract forms are intended for oral use only due to animal-tissue origin.
- Intranasal use is not a Khavinson convention for chonluten and has no published protocol.
- Avoid in eGFR <30 (renal impairment) and in decompensated hepatic disease. Not for paediatric use.
- Chonluten is a speculative adjunct, not a substitute for evidence-graded respiratory care (smoking cessation, inhaled bronchodilators/corticosteroids, pulmonary rehabilitation, vaccinations, and biologics for severe asthma phenotypes).
Evidence
Research & clinical studies (2)
Transport of Biologically Active Ultrashort Peptides Using POT and LAT Carriers
Summarizes molecular-modeling and experimental evidence that ultrashort peptides of 2–7 amino acids, including tissue-specific Khavinson peptides such as chonluten, are transported into cells via POT and LAT family carriers, a mechanism proposed to underlie their tissue specificity and gene-expression regulatory activity.
PMID 35887081Peptide Regulation of Gene Expression: A Systematic Review
Reports that short peptides of 2–7 amino acids can penetrate cell nuclei, interact with histones and DNA, modulate DNA methylation, and regulate gene transcription across multiple species, providing a mechanistic basis for the tissue-specific activities attributed to Khavinson peptides including chonluten.
PMID 34834147Combinations
Stacking & blends
Respiratory bioregulator rotation
Comprehensive respiratory tissue support across seasons
Chonluten (EDG) and Bronchogen (AEDP) are the two Khavinson respiratory bioregulators, positioned as related but distinct sequences. Users alternate or pair them sequentially; no head-to-head or combination evidence establishes superiority, so if budget-constrained, pick one rather than running both simultaneously.
Seasonal immune and respiratory support
Support respiratory tissue plus immune modulation ahead of the winter respiratory-virus season
Within a yearly Khavinson rotation, chonluten covers the respiratory-tissue niche while Thymogen adds immune-peptide activity. Combination is protocol convention, not evidence-backed; Thymosin Alpha-1 is also listed as compatible.
Safety
Side effects & considerations
Commonly reported effects
Contraindications & cautions
- Pregnancy — no reproductive toxicology data
- Breastfeeding — no excretion/infant safety data
- Paediatric use — not studied
- Active lung cancer
- Active tuberculosis
- Acute respiratory infection
- Animal-protein allergy (extract form specifically)
- eGFR <30 and decompensated hepatic disease
Short-term safety signals from Russian literature are mild. The bovine/porcine extract form carries a higher allergic-reaction risk and a theoretical animal-pathogen/prion concern, so the chemically defined synthetic EDG tripeptide is generally the cleaner choice. No placebo-controlled RCTs exist to characterize long-term safety. Continue prescribed inhaled maintenance therapy and inform your pulmonologist of any bioregulator cycles.
FAQ
Chonluten — common questions
What is Chonluten?
Chonluten is a respiratory bioregulator from Vladimir Khavinson's St. Petersburg Institute, marketed in two overlapping forms: a polypeptide extract prepared from bovine or porcine bronchial mucosa, and a defined-sequence synthetic short peptide most commonly cited as the tripeptide Glu-Asp-Gly (EDG). It is positioned to support bronchial epithelium, alveolar function, and airway regeneration.
How is Chonluten different from Bronchogen?
Both are respiratory bioregulators in the Khavinson framework. Chonluten was the original — either the bronchial polypeptide extract or the synthetic Glu-Asp-Gly tripeptide. Bronchogen is the tetrapeptide Ala-Glu-Asp-Pro (AEDP), synthesised as a defined-sequence alternative in the same class with slightly more in vitro and rodent data in English-indexed literature. No head-to-head evidence establishes which is superior.
Does Chonluten actually help with COPD or chronic bronchitis?
The evidence is thin. Russian uncontrolled observational series report subjective improvement and modest spirometry changes after 20–30 day oral cycles, but no placebo-controlled RCTs exist and there is no comparison with inhaled bronchodilators, corticosteroids, or biologics. It is best treated as a speculative adjunct, not a substitute for evidence-graded care.
What is the typical Chonluten dose?
Khavinson convention is a 20 mg oral or sublingual capsule once daily for 10 consecutive days, with 60–90 day washouts, entered in autumn before the winter respiratory season. For synthetic EDG given subcutaneously, 2–5 mg daily for 10 days. The 20 mg capsule contains undisclosed actual active content (historically 2–4 mg), and no dose-ranging trial has established that 20 mg is optimal.
Is Chonluten safe?
Short-term safety signals from Russian literature are mild — occasional nausea, mild headache, rare rash. The extract form has a higher allergic-reaction rate reflecting animal-protein recognition. Pregnancy, breastfeeding, paediatric use, active lung cancer, active TB, and acute respiratory infection are absolute contraindications. Use a third-party verified product with a certificate of analysis.
Should I use the extract or the synthetic EDG tripeptide?
The synthetic EDG tripeptide is generally the cleaner choice — chemically defined, no animal protein, lower allergic-reaction risk, and no prion concern. The polypeptide extract is the historical form, preferred by some who argue the undefined mixture contains bioactivity not captured by the minimised synthetic sequence, but that argument is theoretical.
Can I use Chonluten with inhalers or corticosteroids?
Yes, from an interaction standpoint — no documented pharmacokinetic or pharmacodynamic interactions with inhaled β2-agonists, muscarinic antagonists, or corticosteroids exist, and those drugs act largely locally. Continue inhaled maintenance therapy during chonluten cycles rather than substituting, and notify your pulmonologist.
How does Chonluten compare to other Khavinson peptides?
Chonluten is one of two Khavinson respiratory bioregulators, the other being Bronchogen. Within the broader family (Epitalon, Pinealon, Thymogen, Vilon, Livagen, Cardiogen, Cartalax) it occupies the respiratory niche. Its evidence base is smaller than for Epitalon (most-studied) or Thymogen (most regulatory recognition).
